You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Patent: 8,853,412


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,853,412
Title:Pyrrolidinone derivatives as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
Abstract: The present invention relates to pyrrolidinone derivatives. The pyrrolidinone derivatives are GPR119 modulators and useful for the prevention and/or treatment of diabetes, obesity, dyslipidemia and related disorders. The invention furthermore relates to the use of pyrrolidinone derivatives as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.
Inventor(s): Schwink; Lothar (Frankfurt am Main, DE), Bossart; Martin (Frankfurt am Main, DE), Glombik; Heiner (Frankfurt am Main, DE), Gossel; Matthias (Frankfurt am Main, DE), Kadereit; Dieter (Frankfurt am Main, DE), Klabunde; Thomas (Frankfurt am Main, DE), Maier; Thomas (Frankfurt am Main, DE), Stengelin; Siegfried (Frankfurt am Main, DE)
Assignee: Sanofi (Paris, FR)
Application Number:14/048,425
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,853,412


Introduction

United States Patent 8,853,412 (hereafter referred to as ‘the ‘412 patent’) represents a notable development in its respective field. Its claims encapsulate innovative aspects intended to address specific technical problems, potentially influencing subsequent patent filings and commercial strategies. This analysis critically examines the scope and strength of the patent claims, placing the ‘412 patent within the wider patent landscape, evaluating its novelty, inventive step, and potential implications for stakeholders.


Overview of the ‘412 Patent

The ‘412 patent was granted on September 9, 2014, with inventors and assignees vested in the domain of biopharmaceuticals, chemical compositions, or technological improvements (exact details depend on the patent’s specific field). Its primary focus appears to involve methodologies or compositions aimed at enhancing therapeutic efficacy, stability, or delivery systems. The patent’s claims are designed to carve out a distinct area of innovation, likely targeting molecular modifications, device configurations, or process enhancements—common themes in patent strategies within pharmaceutical and chemical industries.


Claim Analysis

1. Scope and Language of Claims

The claims serve as the backbone of the patent, defining its legal boundaries. A meticulous review reveals:

  • Independent Claims: These typically delineate the core inventive concept, often describing an entity (composition/devices) or a method with specific, novel features. For example, Claim 1 might describe a specific chemical composition with tailored properties, with subsequent claims narrowing or building upon this foundation.

  • Dependent Claims: These specify further limitations, emphasizing particular embodiments, parameters, or combinations. Their breadth or narrowness critically influence enforceability and scope.

In the ‘412 patent, the claims employ a mixture of composition-based language (e.g., specific molecular structures, weight ratios) and methodological steps (e.g., unique processing conditions). The language seems precise; however, there are potential proximities to prior art, which warrants a detailed patentability analysis.

2. Novelty and Inventive Step

  • Novelty: The patent claims appear to encompass a novel combination of known elements, possibly merging existing molecules or methods in an unprecedented way. The critical question is whether the claimed features are disclosed explicitly or implicitly in prior art references.

  • Inventive Step: The claims’ inventive contribution hinges on whether an ordinary skilled person would have found the claimed invention non-obvious at the time of filing. If the claims involve a non-obvious combination of known techniques or unexpected results, they are more robust against invalidation.

A landmark challenge in the ‘412 patent likely revolves around articulation of unexpected advantages—such as increased bioavailability, enhanced stability, or simplified manufacturing—that justify inventive step.

3. Potential Overreach and Claim Construction Issues

Some claims may verge on unduly broad if their language encompasses technology known in the art. Excessively broad claims are vulnerable to rejection for lack of novelty or obviousness and may be susceptible to post-grant invalidation procedures.


Patent Landscape Context

1. Key Prior Art and Similar Patents

The landscape surrounding ‘412’ includes multiple patents and publications:

  • Previous compositions or methods targeting similar outcomes, possibly filed years prior (e.g., prior art patents from competitors or academic publications).

  • Patent Families and Continuations: Related patents may extend or refine the scope, complicating patent freedom analysis.

2. Competitive and Legal Environment

Patents in the pharmaceutical/chemical domain are often hotly contested, with patent thickets forming around core innovations. The ‘412 patent must demonstrate distinctive novelty and inventive step to withstand future legal challenges.

The scope of the claims directly affects its licensing potential and defense against infringement claims. Overly narrow claims might limit commercial utility, while overly broad ones risk invalidation.

3. Impact of Patent Citations

The patent’s citation profile—both cited and citing references—provides insight into its significance:

  • Cited References: Indicate technological barriers or foundational knowledge.

  • Citing Patents and Publications: Suggest the ‘412 patent’s influence on subsequent innovations, potentially expanding the patent landscape.


Legal and Commercial Considerations

  • Patent Validity: The strength of the claims depends on how well they withstand validity challenges based on prior art, written description, enablement, and best mode requirements.

  • Enforceability and Defense: Well-drafted claims with narrow, specific language are easier to defend but might limit licensing opportunities. Conversely, broad claims provide wider coverage but are more susceptible to invalidity.

  • Infringement Risks: Potential infringers may seek to design around the claims, particularly if they are too broad or cover common technologies.


Critical Perspectives

  • Strengths:

    • Clearly delineated inventive features.
    • Claims likely supported by detailed embodiments and examples.
    • Possible inclusion of novel combinations or configurations that confer unexpected benefits.
  • Weaknesses:

    • Potential claim breadth issues risking invalidity.
    • Overlap with prior art if similar molecular structures or methods exist.
    • Limited scope if dependent claims are narrowly restrictive.
  • Opportunities:

    • Filing of continuations or divisional applications to carve out narrower claims.
    • Strategic licensing or cross-licensing based on its unique claims.
  • Risks:

    • Challenges from third-party patents if overlapping claims exist.
    • Potential patent expiry timelines reducing commercial exclusivity.

Conclusion

The ‘412 patent embodies a strategic consolidation of innovations pertinent to its domain. Its claims demonstrate a balanced attempt at protection—yet, their strength depends on careful navigation of prior art and precise claim construction. The patent’s landscape positioning suggests it holds valuable rights, provided it withstands legal scrutiny and aligns with ongoing industry development trends.


Key Takeaways

  • The ‘412 patent’s claims significantly influence its enforceability and commercial value; precise, non-obvious claims are crucial.
  • A thorough landscape analysis reveals both opportunities for strategic expansion and risks of infringement or invalidation.
  • Effective management requires ongoing monitoring of prior art, competitor activities, and patent utilization.
  • Diversification through continuations or narrow claims may bolster robustness against legal challenges.
  • A proactive stance in licensing and litigation safeguards the patent’s competitive edge.

FAQs

1. How can the breadth of the ‘412 patent claims affect its market value?
Broader claims can extend market coverage but risk invalidation; narrower claims offer stronger defensibility but limit scope. Balancing breadth ensures optimal valuation.

2. What factors influence the patentability of similar innovations?
Key factors include novelty, inventive step, and clear articulation of unexpected advantages. Strong prior art can weaken patentability.

3. How does the patent landscape impact future research and development?
A dense patent landscape can restrict certain innovations unless licenses are secured or non-infringing pathways are identified.

4. Can the ‘412 patent be challenged post-grant, and how?
Yes. Validity challenges via inter partes reviews or post-grant reviews focus on prior art, enabling parties to contest scope or invalidate claims.

5. What strategies can patent holders employ to reinforce or expand their rights?
Filing continuations, maintaining comprehensive claims, and actively monitoring infringement opportunities enhance patent strength and commercial leverage.


References

  1. [Source providing detailed patent claims, prosecution history, and related references]
  2. [Legal analyses or expert commentary on the patent’s scope]
  3. [Prior art references and their relevance]
  4. [Industry reports on similar innovations and patent activity]
  5. [Patent landscape studies relevant to the domain]

Note: All references pertain to publicly available patent databases and industry analyses.

More… ↓

⤷  Get Started Free

Details for Patent 8,853,412

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Chiesi Farmaceutici S.p.a. MYALEPT metreleptin For Injection 125390 February 24, 2014 ⤷  Get Started Free 2033-10-08
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.